Business
Research on Lodonal (“LDN”) for HIV-related GI complications, and Inflammation featured in A&U Magazine
Research on Lodonal (“LDN”) for HIV-related GI complications, and Inflammation featured in A&U Magazine.
About this update from Biostax Corp.
[{"type":"text","content":"\nORLANDO, Fla., Dec. 13, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB:IMUN) (\"Immune\" “IMUN” or the \"Company\"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS announced today that their lead therapy, Lodonal™  (LDN), was featured in an article published in A&U Magazine (https://issuu.com/aumagazine/docs/a_u_december2018 pg. 59).\n The article, titled “The Next Waltz,” cited studies suggesting Lodonal’s potential for changing the course of the epidemic by treating HIV-related comorbidities driven by inflammation such as Chron’s disease, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS).  Addressing that, “existing medications to treat inflammatory bowel diseases (IBD), such as Crohn’s disease and irritable bowel syndrome (IBS), can cause significant immune suppression which can be more damaging in PLWHAs than those with IBD alone.” The author goes on to say; “Lodonal is hopefully the first in a line of new therapies needed for people living with HIV and Crohn’s or IBS.”  The comprehensive article also shows studies suggesting Lodonal™ and LDN ’s potential “…to enhance the immune system,” demonstrating “…CD4 recovery that was attributed to decreases in inflammatory cytokines.” Another study mentioned, from the University of Minnesota, discovered that “Naltrexone affected HIV expression in CD4 lymphocyte cultures which play a role in the potentiation of antiretroviral drugs and suggest that clinical trials should be considered of naltrexone as an adjunctive therapy of HIV infection.”  Dr. David Malebranche Associate Professor at the Moorehouse School of Medicine, is quoted in article saying that “Naltrexone would be a good intervention option for HIV-positive people.” and points out that, “As a medical and research community we focus on interventions such as bnAbs [broadly neutralizing antibodies], two drug regimens, vaccines, etc., and forget about intersecting epidemics.” The author surmised that: “Separately, and collectively, these studies indicate that Naltrex...